Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business HighlightsGlobeNewsWire • Thursday
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney WeekGlobeNewsWire • Monday
Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumGlobeNewsWire • 10/07/26
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026GlobeNewsWire • 10/06/26
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 10/01/26
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney DiseasesGlobeNewsWire • 09/14/26
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in BostonGlobeNewsWire • 09/01/26
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/05/26
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business HighlightsGlobeNewsWire • 08/05/26
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney DiseasesGlobeNewsWire • 08/03/26
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business HighlightsGlobeNewsWire • 07/29/26
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESAGlobeNewsWire • 06/30/26
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones NearMarketBeat • 06/05/26
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/28/26
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/07/26
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline HighlightsGlobeNewsWire • 05/07/26
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of NephrologyGlobeNewsWire • 05/04/26
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business HighlightsGlobeNewsWire • 04/30/26
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090GlobeNewsWire • 04/13/26
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation SymposiumGlobeNewsWire • 04/07/26